Solution reagent CL-ASC-0 series

antibodypathologyprotein

Standard control for “MagQu” α-Synuclein IMR Reagent (MF-ASC-006B) “MagQu” α-Synuclein Control Solution is used as a standard control for “MagQu” α-Synuclein IMR Reagent (MF-ASC-006B). Introduction α-Synuclein (SNCA) is a presynaptic neuronal protein and is abundant in the human brain. α-Synuclein aggregates to form insoluble fibrils in pathological conditions characterized by Lewy bodies, such as Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). These disorders are known as synucleinopathies. α-Synuclein is the primary structural component of Lewy body fibrils. Occasionally, Lewy bodies contain tau protein; however, α-Synuclein and tau constitute two distinctive subsets of filaments in the same inclusion bodies. α-Synuclein pathology is also found in both sporadic and familial cases with Alzheimer's disease.1, 2, 3 Principle of Test α-Synuclein Control Solution is used as a standard control for “MagQu” α-Synuclein IMR Reagent (MF-ASC-006B). The antibody conjugated on the surface of Fe3O4 magnetic particles (~ 50 nm) could bind with α-Synuclein and form clusters. With the increase of cluster, the signal of ac susceptibility ( χac ) will decrease in the applied ac magnetic field. That is the principle of Immuno Magnetic Reduction (IMR). By measuring the reduction of χac , we can quantify the α-Synuclein in the sample easily and accurately.